Pharmaceuticals company Lupin announced Q2FY27 results Consolidated Financial Highlights: Revenue from operations: For Q2FY27, consolidated revenue from operations stood at Rs 78,272.6 million, registering a QoQ decline of 5.43% compared to Rs 82,768.9 million in Q1FY27 and a YoY growth of 11.06% compared to Rs 70,475.1 million in Q2FY26; for H1FY27, it reached Rs 161,041.5 million, up by 20.94% YoY against Rs 133,158.5 million in H1FY26. Total income: For Q2FY27, consolidated total income was Rs 79,540.5 million, down by 5.39% QoQ from Rs 84,072.1 million in Q1FY27 and up by 11.44% YoY from Rs 71,375.1 million in Q2FY26; for H1FY27, total income stood at Rs 163,612.6 million, recording a YoY growth of 21.33% compared to Rs 134,848.9 million in H1FY26. Profit before tax (PBT): For Q2FY27, consolidated profit before tax was Rs 15,796.0 million, showing a decline of 21.70% QoQ from Rs 20,173.6 million in Q1FY27 and a decline of 21.29% YoY from Rs 20,069.7 million in Q2FY26; for H1FY27, PBT reached Rs 35,969.6 million, expanding by 5.10% YoY compared to Rs 34,225.1 million in H1FY26. Profit after tax (PAT): For Q2FY27, consolidated net profit after tax was Rs 11,553.0 million, down by 18.47% QoQ from Rs 14,169.8 million in Q1FY27 and down by 22.19% YoY from Rs 14,848.3 million in Q2FY26; for H1FY27, PAT stood at Rs 25,722.8 million, showing a YoY decrease of 4.95% compared to Rs 27,062.9 million in H1FY26. Earnings per share (EPS): For Q2FY27, basic EPS (after exceptional items) was Rs 25.27, representing a QoQ drop of 18.35% from Rs 30.95 in Q1FY27 and a YoY drop of 21.91% from Rs 32.36 in Q2FY26; for H1FY27, basic EPS was Rs 56.21, a decrease of 4.81% YoY compared to Rs 59.05 in H1FY26. Standalone Financial Highlights: Revenue from operations: For Q2FY27, standalone revenue from operations stood at Rs 35,673.4 million, reflecting a QoQ decrease of 50.26% compared to Rs 71,719.0 million in Q1FY27 and a YoY decline of 12.31% compared to Rs 40,682.8 million in Q2FY26; for H1FY27, it was Rs 107,392.4 million, showing a growth of 9.84% YoY against Rs 97,768.7 million in H1FY26. Total income: For Q2FY27, standalone total income was Rs 36,628.6 million, down by 49.65% QoQ from Rs 72,743.8 million in Q1FY27 and down by 11.49% YoY from Rs 41,382.8 million in Q2FY26; for H1FY27, it recorded Rs 109,372.4 million, which is a 10.47% increase YoY compared to Rs 99,010.1 million in H1FY26. Profit before tax (PBT): For Q2FY27, standalone profit before tax dropped to Rs 41.9 million, down 99.88% QoQ from Rs 36,100.6 million in Q1FY27 and down 99.74% YoY from Rs 16,358.1 million in Q2FY26; for H1FY27, PBT stood at Rs 36,142.5 million, a decrease of 14.44% YoY compared to Rs 42,239.6 million in H1FY26. Profit after tax (PAT): For Q2FY27, standalone net profit after tax recorded a net loss of Rs 59.1 million, compared to a profit of Rs 27,146.0 million in Q1FY27 and a profit of Rs 13,573.5 million in Q2FY26; for H1FY27, PAT stood at Rs 27,086.9 million, down by 22.28% YoY compared to Rs 34,854.2 million in H1FY26. Earnings per share (EPS): For Q2FY27, basic EPS (after exceptional items) turned negative at Rs (0.13), compared to Rs 59.37 in Q1FY27 and Rs 29.72 in Q2FY26; for H1FY27, basic EPS was Rs 59.24, down 22.38% YoY from Rs 76.32 in H1FY26. Business Highlights: Pharmaceuticals Segment Performance: For Q2FY27, the Pharmaceuticals segment revenue was Rs 77,756.3 million, experiencing a QoQ drop of 5.57% from Rs 82,343.5 million in Q1FY27 and a YoY growth of 10.92% from Rs 70,103.2 million in Q2FY26; segment results (profit before tax) for Q2FY27 stood at Rs 16,138.4 million. For H1FY27, segment revenue was Rs 160,099.8 million (up 20.86% YoY) and segment results were Rs 36,744.0 million. Others Segment Performance: For Q2FY27, the Others segment revenue was Rs 521.2 million, up by 21.13% QoQ from Rs 430.3 million in Q1FY27 and up by 38.32% YoY from Rs 376.8 million in Q2FY26; it recorded a segment loss before tax of Rs 342.4 million in Q2FY27. For H1FY27, segment revenue stood at Rs 951.5 million (up 36.01% YoY) with a segment loss of Rs 774.4 million. Nilesh Gupta, Managing Director, Lupin, said: "We delivered a strong H1FY27, underpinned by solid growth across key markets and sustained profitability. While we remain mindful of near-term challenges, we are confident in our long-term growth prospects, supported by the strength of our portfolio, continued investments in R&D; and commercial capabilities, and our unwavering focus on disciplined execution." Result PDF